Takeaways
#- Lund thought small caps could join the large-cap rally without the leaders first having to fall.
- Parets saw rotation already underway in small caps relative to large caps and in the equal-weight S&P 500 relative to the capitalization-weighted index.
- Lund was looking for possible bottoms in Halozyme and CRISPR Therapeutics, alongside a possible turn in XBI.
Brian Lund could picture two very different mornings producing the same headline. If the biggest technology stocks sold off, a news report might say the market was falling. That would tell a trader little about smaller companies that were starting to rise. On the December 6, 2023 Morning Show, Lund asked Spencer Israel, JC Parets and Steve Strazza whether those smaller stocks needed the leaders to fall at all.
The iShares Russell 2000 ETF (IWM) had broken out the previous week while the large-cap indexes paused. Then small caps took a breather of their own. Lund thought it was possible for all four major U.S. indexes to advance together into year-end. The harder question was what to do with stocks that had barely moved during the rally. Some might be the next group to go up. Others might be weak for good reason and fall further if the market turned.
What the relative charts added
Parets put more weight on rotation. The S&P 500 and Nasdaq were approaching their old highs, where buyers might meet sellers again. Small caps, by contrast, had already started to gain on large caps. An equally weighted version of the S&P 500 had also reached a multimonth high against its capitalization-weighted counterpart. More money didn't have to flow into the biggest companies for that relative move to continue.
Why Lund pulled up biotech
Lund thought the SPDR S&P Biotech ETF (XBI) might have formed a bottom. He wanted to see whether individual biotech charts showed the same change. A low in a fund that owned many stocks would be more useful to him if he could also identify a company whose own decline was ending.
He named Halozyme Therapeutics and CRISPR Therapeutics as two he wanted to keep an eye on. That was a different list from the biotechs he considered strong already. Lund was looking for early evidence that buyers had come back to those two stocks; he didn't yet know whether they would join the leaders.
Questions and answers
#Questions answered in the original 2023-12-06 episode.
Why did Lund think a headline about falling stocks could be misleading?
A decline in heavily weighted technology names could dominate the headlines even as smaller stocks rose. He wanted to know which individual names were actually moving.
What was Lund watching in biotech?
He thought XBI might have formed a bottom and wanted to see whether similar patterns were appearing in individual names. Halozyme and CRISPR Therapeutics were among his candidates.
Adapted by Stock Market TV Editorial from the original video. Source date: . Article published: .